$NVAX Well folks, so much information to chew . Not now let’s enjoy . Most positive Earnings Call Novavax has ever had with not only nuggets but Golden boulders of information. JJ at the end sounded like he was giving an acceptance speech and just won an Oscar for Best Biotech. Most analysts still clueless, surprised at all those idiotic questions. Most still modeling Novavax as a Covid company. Still don’t grasp the true potential of matrix m. My speculation is Merck is the BP that expanded the MTA to oncology that they say was signed in February. Brian Foard the architect of the Sanofi/Novavax original agreement, the Point man JJ dealt with everyday for the past two years is going to join Merck on March 2nd to head the split Merck division that would be involved in any Novavax negotiations. Yea I think it’s Merck and yea I think it’s Keytruda.
Also $NVAX one thought, this is the first company to ever build out this model, the market has no peer group to use as a valuation tool, there are not predictable cash flows yet, so no multiple to assign to it, the market doesn't know yet how to price this model .... I have been down on JJ, still disappointed no partner for CIC/Flu (we need that partner), however, Nova is forging new territory with a research/adjuvant based model of business with a few of it's own products and whole slew of partnerships ..... I do feel better about Nova after this call than I have in several years